Acumen Pharmaceuticals (ABOS) Stock Price
$1.16 3.6%
to add to portfolio
AI Score
-
Alternative
3 -
Fundamental
1 -
Technical
3
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Acumen Pharmaceuticals, AI stock picks, stock alerts and much more.
ABOS AI Stock Analysis
AI stock analysis for ABOS is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Acumen Pharmaceuticals (ABOS) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Acumen Pharmaceuticals (ABOS) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Acumen Pharmaceuticals (ABOS), currently trading at $1.16, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About ABOS
-
Acumen Pharmaceuticals, Inc.
-
Symbol
ABOS
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
70.3M
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$21.7 0.4% |
6 |
 |
Inovio Pharmaceuticals INO |
$2.04 3.6% |
3 |
 |
Moderna MRNA |
$27.59 1.6% |
3 |
 |
Anavex Life Sciences AVXL |
$9.22 2.7% |
6 |
 |
BridgeBio Pharma BBIO |
$43.18 3.7% |
7 |
News
ABOS Alternative Data
Web Traffic
Acumen Pharmaceuticals receives an estimated 4516 monthly visitors to acumenpharm.com.
-
Web Traffic
4516
-
Change from Previous Month
19.5%
-
3 Month Change
7.6%
-
YoY Change
7.6%
Facebook Engagement
Acumen Pharmaceuticals has engaged 6 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
6
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
50%
-
YoY Change
50%
Instagram Followers
Acumen Pharmaceuticals has 115 Instagram Followers on its main Instagram account.
-
Instagram Followers
115
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
1.7%
-
YoY Change
1.7%
LinkedIn Followers
5,889 are following Acumen Pharmaceuticals on LinkedIn, up by 0.9% over the last month.
-
LinkedIn Followers
5889
-
Daily Change
0%
-
1 Month Change
0.9%
-
3 Month Change
5%
Job Postings
Acumen Pharmaceuticals has an estimated 0 open job postings, which is down -100% over the last month.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
100%
-
3 Month Change
100%
-
YoY Change
100%
LinkedIn Employees
According to LinkedIn, Acumen Pharmaceuticals has 68 employees, up by 1.5% over the last month.
-
LinkedIn Employees
68
-
Daily Change
0%
-
1 Month Change
1.5%
-
3 Month Change
5.6%
-
YoY Change
5.6%
Reddit Mentions
Acumen Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Twitter Followers
Acumen Pharmaceuticals has 268 Twitter Followers on its main Twitter (also known as X) account.
-
Twitter Followers
268
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
3.1%
-
YoY Change
3.1%
News Mentions
Acumen Pharmaceuticals was mentioned 1 times in the news yesterday.
-
News Mentions
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
ABOS Financials
ABOS Key Metrics
-
Total Revenue
$0
-
Net Income
-$29.8M
-
Earnings per Share
-$0.5
-
Free cash flow
-$24.6M
-
EBITDA
-$28.7M
-
EBITDA Ratio
0
-
Total Assets
$239M
ABOS 2-year Revenue & Income
ABOS 2-year Free Cash Flow
ABOS Technicals
ABOS SMA
ABOS RSI
FAQ
What's the current price of Acumen Pharmaceuticals (ABOS) Stock?
The price of an Acumen Pharmaceuticals (ABOS) share is $1.16.
What's the market cap of Acumen Pharmaceuticals?
The current market cap of Acumen Pharmaceuticals is 70.3M.
Should I buy or sell ABOS?
Acumen Pharmaceuticals exhibits several negative alternative data signals, leading us to expect continued underperformance in the coming months. As a result, we maintain a negative outlook on this stock.
Is Acumen Pharmaceuticals a good investment?
Considering the fundamentals, technical analysis, and alternative data insights, it may not be the best time to invest in Acumen Pharmaceuticals stock. There are several bearish signals and market challenges that could negatively impact Acumen Pharmaceuticals' future performance, suggesting that caution should be exercised before making any investment decisions.
Is now a good time to buy Acumen Pharmaceuticals (ABOS) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it may not be the best time to buy Acumen Pharmaceuticals stock right now, as the outlook appears bearish.
What are some stocks similar to Acumen Pharmaceuticals (ABOS) that investors often compare it to?
Acumen Pharmaceuticals (ABOS) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Acumen Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Acumen Pharmaceuticals' stock price to be around $1.05 in 2026. Starting from the current price of $1.16, this represents a 9.8% change in price, indicating a bearish outlook for the stock.
How to buy Acumen Pharmaceuticals (ABOS) Stock?
Acumen Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Acumen Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.